Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPHA2: ALLO-501A and ALLO-647 in R/R LBCL and CLL/SLL
NCT04416984Phase 2Active, not recruiting
- Sponsor
- Allogene Therapeutics
- Start
- May 2020
- Primary completion
- Feb 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of cemacabtagene ansegedleucel in diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Allogene Therapeutics. Started May 2020; status: active, not recruiting.
02
Drugs
cemacabtagene ansegedleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04416984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416984.